Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherANALGESIA AND DRUGS OF ABUSE

Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement ,

H. R. Garner, Timothy F. Burke, C. David Lawhorn, Joanne M. Stoner and William D. Wessinger
Journal of Pharmacology and Experimental Therapeutics September 1997, 282 (3) 1253-1261;
H. R. Garner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy F. Burke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. David Lawhorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne M. Stoner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William D. Wessinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In the present experiments, we characterized the agonist and antagonist effects of butorphanol in mice. In the mouse radiant-heat tail-flick test, the mu agonists morphine and fentanyl and thekappa agonist U50,488H were fully effective as analgesics, whereas butorphanol was partially effective (producing 82% of maximal possible analgesic effect). Naltrexone was approximately equipotent in antagonizing the effects of morphine, fentanyl and butorphanol;in vivo apparent pA 2 values for these naltrexone/agonist interactions were 7.5 (unconstrained). Naltrexone was ∼10 times less potent in antagonizing the effect of U50,488H (average apparent pKB = 6.7). The selectivemu antagonist β-funaltrexamine (0.1–1.0 mg/kg) antagonized the effects of butorphanol in a dose-dependent insurmountable manner. Pretreatment with nor-binaltorphimine (32 mg/kg), a kappa-selective antagonist, did not reliably antagonize butorphanol, and naltrindole (20 and 32 mg/kg), adelta-selective antagonist, failed to antagonize the effects of butorphanol. Low doses of butorphanol (1.0, 1.8 or 3.2 mg/kg) caused parallel, rightward shifts in the dose-effect curve for morphine and parallel leftward shifts in the dose-effect curve for U50,488H. Taken together, the results of the present study suggest that butorphanol is a partial agonist in the mouse radiant-heat tail-flick test and that activity at mu receptors accounts for the majority of its antinociceptive effects.

Footnotes

  • Send reprint requests to: Dr. William D. Wessinger, University of Arkansas for Medical Sciences, Department of Pharmacology and Toxicology, Slot 611, 4301 W. Markham Street, Little Rock, AR 72205. E-mail: wdwessinger{at}life.uams.edu

  • ↵1 A preliminary report of these findings was presented at the International Anesthesiology Research Society (IARS) meeting in Washington, DC, March 1996.

  • ↵2 This study was supported by the Division of Pediatric Anesthesia, Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, AR, and the UAMS Graduate Student Research Fund. H.R.G. was supported by a predoctoral fellowship funded by NIDA Training Grant DA07260.

  • ↵3 Present address: Johns Hopkins University School of Medicine, Behavioral Pharmacology Research Unit, 5510 Nathan Shock Dr., Suite 3000, Baltimore, MD 21224.

  • ↵4 Present address: Astra Merck, Inc., 3838 N. Causeway Blvd., Lakeway III, Ste. 2400, Metairie, LA 70002.

  • ↵5 Present address: 4401 Heritage Dr., Lawrence, KS 66047.

  • Abbreviations:
    %MPE
    % maximum possible effect
    β-FNA
    β-funaltrexamine
    nor-BNI
    nor-binaltorphimine
    CL
    confidence limit
    • Received November 20, 1996.
    • Accepted May 23, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 3
1 Sep 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement ,
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherANALGESIA AND DRUGS OF ABUSE

Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement ,

H. R. Garner, Timothy F. Burke, C. David Lawhorn, Joanne M. Stoner and William D. Wessinger
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1253-1261;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherANALGESIA AND DRUGS OF ABUSE

Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement ,

H. R. Garner, Timothy F. Burke, C. David Lawhorn, Joanne M. Stoner and William D. Wessinger
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1253-1261;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats
  • Delta Opioid Receptor Enhancement ofMu Opioid Receptor-Induced Antinociception in Spinal Cord
  • Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs1
Show more ANALGESIA AND DRUGS OF ABUSE

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics